-
61
Vascular response patterns to targeted therapies in murine breast cancer models with divergent degrees of malignancy
Published 2023-05-01“…In the low malignant 67NR model, ICI treatment also mediated vessel-stabilizing effects with decreased tumor perfusion and permeability, while ICI-treated 4T1 tumors exhibited increasing tumor perfusion with excessive vascular leakage. …”
Get full text
Article -
62
Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice
Published 2022-04-01“…Although breast cancer (BC) has been historically considered a “cold tumor”, exciting progress in the genomic field leading to the characterization of the molecular portrait and the immune profile of TNBC has opened the door to novel therapeutic strategies, including Immune Checkpoint Inhibitors (ICIs), Poly ADP-Ribose Polymerase (PARP) inhibitors and Antibody Drug Conjugates (ADCs). …”
Get full text
Article -
63
Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer
Published 2022-10-01“…Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of many solid tumors. …”
Get full text
Article -
64
A circadian rhythm-related gene signature for prognosis, invasion and immune microenvironment of breast cancer
Published 2023-01-01“…Background: Circadian dysregulation is linked to the onset and progression of cancer, but current knowledge of the role of circadian rhythm-related genes (CRRGs) in breast cancer (BC) is limited and incomplete. The purpose of this study was to investigate the potential role and immune-related prognostic significance of CRRGs in BC.Methods: The Cancer Genome Atlas breast cancer (TCGA-BRCA) genetic data were combined with 1369 CRRGs to create a model of BC prognosis-related CRRGs. …”
Get full text
Article -
65
Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications
Published 2024-01-01“…Compared to highly immunogenic tumor types, such as melanoma or lung cancer, breast cancer has been viewed as an immunologically quiescent tumor which displays a relatively low population of tumor-infiltrating lymphocytes (TIL), low tumor mutational burden (TMB) and modest response rates to immune checkpoint inhibitors (ICI). …”
Get full text
Article -
66
Multi-Gene Testing Overview with a Clinical Perspective in Metastatic Triple-Negative Breast Cancer
Published 2021-07-01“…In this review, we analyze available NGS platforms and clinical applications of multi-gene testing in breast cancer, with a focus on metastatic triple-negative breast cancer (mTNBC). …”
Get full text
Article -
67
Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type
Published 2023-04-01“…Breast cancer is a heterogeneous disease with different molecular subtypes. …”
Get full text
Article -
68
Pathological Complete Response to Neoadjuvant Chemoimmunotherapy for Early Triple-Negative Breast Cancer: An Updated Meta-Analysis
Published 2022-06-01“…Immune checkpoint inhibitors (ICIs) have made a breakthrough in the systemic treatment for metastatic triple-negative breast cancer (TNBC) patients. …”
Get full text
Article -
69
The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis
Published 2022-11-01“…Conclusion Meta-analysis revealed that the prognostic relevance of TMB in breast cancer is limited in scope. High TMB may be associated with longer survival only in ICIs-based treatment, but the association is not evident in non-ICIs-based treatment. …”
Get full text
Article -
70
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group
Published 2021-12-01“…Abstract The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. …”
Get full text
Article -
71
Landscape of prognosis and immunotherapy responsiveness under tumor glycosylation-related lncRNA patterns in breast cancer
Published 2022-09-01“…Aberrant glycosylation, a post-translational modification of proteins, is regarded to engage in tumorigenesis and malignant progression of breast cancer (BC). The altered expression of glycosyltransferases causes abnormal glycan biosynthesis changes, which can serve as diagnostic hallmarks in BC. …”
Get full text
Article -
72
Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer
Published 2023-08-01“…BackgroundData supporting high tumor mutational burden (TMB-H) as a lone biomarker for an immune-responsive tumor microenvironment (TME) in metastatic breast cancer (MBC) are weak, yet tumor agnostic approval in TMB-H advanced tumors provides immune checkpoint inhibition (ICI) as a clinical option. …”
Get full text
Article -
73
Multiparametric chemical exchange saturation transfer MRI detects metabolic changes in breast cancer following immunotherapy
Published 2023-08-01“…Methods Tumor characteristics of highly malignant 4T1 and low malignant 67NR murine breast cancer models were investigated, and their changes during tumor progression and immune checkpoint inhibitor (ICI) treatment were evaluated. …”
Get full text
Article -
74
Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer
Published 2023-03-01“…The advent of immunotherapy, especially immune checkpoint inhibitors (ICIs), has revolutionized antitumor therapy. Programmed cell death receptor 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are among the most promising targets for encouraging the immune system to eliminate cancer cells. …”
Get full text
Article -
75
Alterations in Progesterone Receptor Isoform Balance in Normal and Neoplastic Breast Cells Modulates the Stem Cell Population
Published 2020-09-01“…Flow cytometry and mammosphere assays revealed that in murine breast, overexpression of PRB leads to an increase in luminal and basal progenitor/stem cells. …”
Get full text
Article -
76
<it>AIB1 </it>gene amplification and the instability of polyQ encoding sequence in breast cancer cell lines
Published 2006-05-01“…<p>Abstract</p> <p>Background</p> <p>The poly Q polymorphism in <it>AIB1 </it>(amplified in breast cancer) gene is usually assessed by fragment length analysis which does not reveal the actual sequence variation. …”
Get full text
Article -
77
PTPRO-related CD8+ T-cell signatures predict prognosis and immunotherapy response in patients with breast cancer
Published 2022-08-01“…Of note, the PTS could accurately predict the response to immune checkpoint inhibitors (ICIs).ConclusionPTPRO significantly impacts CD8+ T-cell infiltration in breast cancer, suggesting a potential role of immunomodulation. …”
Get full text
Article -
78
Peptide self-assembled nanomedicine induces antitumor immunity by blocking the PD-1/PD-L1 axis
Published 2022-12-01Get full text
Article -
79
-
80
Construction and validation of a gene expression classifier to predict immunotherapy response in primary triple-negative breast cancer
Published 2023-07-01“…Abstract Background Immune checkpoint inhibitors (ICI) improve clinical outcomes in triple-negative breast cancer (TNBC) patients. …”
Get full text
Article